Naurex has announced the issuance of new US patent for selective NMDA receptor partial agonist, GLYX-13, covering methods of treating major depressive disorder through 2030.
In a Phase II trial, GLYX-13 demonstrated considerable safety, efficacy profile with rapid onset of effect within hours of a single dose.
Naurex CEO Derek Small said issuance of the new patent extending protection for GLYX-13 adds significant value to the company's depression program.
"In addition, we are continuing to pursue additional patents for GLYX-13 to further fortify our patent portfolio for this promising new drug," Small added.
Presently, GLYX-13 is being assessed in a 400-subject Phase Il repeated dose trial, while initial Phase II trial data demonstrated that the compound significantly reduced depression scores in subjects failing to respond to treat current antidepressants.
